Endocrine Abstracts

Introduction: CLM29, a pyrazolo[3,4-d]pyrimidine compound, inhibits several targets (including the RET tyrosine kinase, epidermal growth factor receptor, vascular endothelial growth factor receptor and has an anti-angiogenic effect). Recently it has been shown to inhibit proliferation and migration in primary papillary dedifferentiated thyroid cancer cells. The aim of this study is to evaluate the anti-tumor activity of CLM29 in medullary thyroid cancer (MTC).<p c...

Anaplastic thyroid cancer (ATC) is usually treated with surgery, external hyperfractionated radiation therapy, and chemotherapy. However, because of the aggressiveness of this type of cancer, these treatments allow about 6-10 months of median survival. Therefore, it is challenging to predict the ATC patient clinical therapy responsiveness. Pazopanib is a multitarget tyrosine kinase inhibitor of VEGF receptors, PDGF, and c-Kit, and its effect in primary human ATC cells (pATC) h...